All In Biotech

Drug Trial Radar · NCT02791230

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM)

Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,733

Actual

Start

Jun 13, 2016

Primary completion

Oct 26, 2023

Study completion Nov 2, 2023

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 6, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy

Conditions

  • Transthyretin (TTR) Amyloid Cardiomyopathy

Interventions

  • TafamidisDrug

    Soft gel capsules administered once a day for 60 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to All-Cause Mortality: Cohort ATime frame: From first dose of randomized treatment in parent study (B3461028) up to 28 days post last dose of study treatment in current extension study (B3461045), [approximately up to 91 months]
  2. Number of Participants With All-Cause Mortality Events: Cohort BTime frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
  3. Number of Participants With Treatment-Emergent Adverse Events (AEs)Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)

Locations

80 sites in 17 countries. Site status is shown where the registry gives one.

  • The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama

  • Cardiovascular Clinical Trials Unit (CCTU)

    Birmingham, Alabama

  • University Hospital, University of Alabama at Birmingham

    Birmingham, Alabama

  • California Heart Center

    Beverly Hills, California

  • Cedars-Sinai Medical Care Foundation

    Beverly Hills, California

  • Altman Clinical Translational Research Institute

    La Jolla, California

  • University of California, San Diego

    La Jolla, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California, San Diego Medical Center - Hillcrest

    San Diego, California

  • Center Adv Lab Medicine

    San Diego, California

  • UCSF Ambulatory Care Center

    San Francisco, California

  • University of California

    San Francisco, California

  • UCSF Cardiovascular Care and Prevention Center

    San Francisco, California

  • Stanford University Hospital and Clinics

    Stanford, California

  • Sylvester at Deerfield Beach

    Deerfield Beach, Florida

  • University of Miami Hospital & Clinics/Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Northwestern Medical Group

    Chicago, Illinois

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Advocate Christ Medical Center

    Oak Lawn, Illinois

  • University of Maryland, Baltimore

    Baltimore, Maryland

  • Johns Hopkins University

    Baltimore, Maryland

  • Boston Medical Center Investigational Pharmacy

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • Boston University Medical Center

    Boston, Massachusetts

  • Michigan Medicine,University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic Hospital-Rochester

    Rochester, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Newark Beth Israel Medical Center

    Newark, New Jersey

  • NYU Langone Health

    New York, New York

  • Center for Advanced Cardiac Care

    New York, New York

  • Columbia University Irving Medical Center

    New York, New York

  • Duke University

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • OHSU Center for Health and Healing

    Portland, Oregon

  • OHSU Research Pharmacy Services

    Portland, Oregon

  • Oregon Health & Science University

    Portland, Oregon

  • Penn Presbyterian Medical Center

    Philadelphia, Pennsylvania

  • Vanderbilt Univ. Med. Ctr

    Nashville, Tennessee

  • Huntsman Cancer Hospital

    Salt Lake City, Utah

  • University of Utah Hospitals & Clinics

    Salt Lake City, Utah

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.